Sign In
Buy NVO
$47.42
+1.52 (+3.31%)
At Close: Jun 23, 2026
Novo Nordisk's Ozempic to take center stage when the pharma giant reports 3Q earnings next week
11:23am, Tuesday, 24'th Oct 2023
Novo Nordisk (NYSE:NVO) is scheduled to report earnings on November 2 before the opening bell The Street consensus for Novo Nordisk (NYSE:NVO) is earnings of $0.71 per share on revenue of $7.91 billio
Novo Nordisk Milks The Obesity Cash Cow - How Long Will It Last?
09:30am, Tuesday, 24'th Oct 2023
NVO's obesity/diabetes drug, Wegovy/Ozempic, is projected to outperform the best-selling drug of all time, Humira, with an estimated $38.5B in annual sales by 2030. This has led to the stock's inflate
Novo Nordisk: Growing To Potentially Become The First Trillion-Dollar European Champion
01:24am, Tuesday, 24'th Oct 2023
Novo Nordisk stock has tripled since 2020 and is up over 30% YTD; but there is still upside. Novo is poised to benefit from the surging demand for diabetes and obesity care, with an estimated annual T
Novo Nordisk (NVO) Advances While Market Declines: Some Information for Investors
07:33pm, Monday, 23'rd Oct 2023
The latest trading day saw Novo Nordisk (NVO) settling at $97.12, representing a +0.86% change from its previous close.
Ozempic Maker Novo Nordisk Has a Weight Problem
11:39am, Monday, 23'rd Oct 2023
What happens when one company accounts for more than half of a stock index?
3 Healthcare Stocks to Invest in for a Big Shot of Gains
07:30am, Monday, 23'rd Oct 2023
With a few exceptions, healthcare stocks have had a rough go of it in 2023. The Standards and Practices (S&P) 500 Healthcare Index is down 5% year to date, versus a 13% increase in the benchmark S&P 5
Eli Lilly, Novo Nordisk to test weight loss drugs for children
11:00am, Sunday, 22'nd Oct 2023
Pharmaceutical manufacturers Eli Lilly (LLY) and Novo Nordisk (NVO) are reportedly planning to test their weight loss drugs for children six and older. Yahoo Finance Health Reporter Anjalee Khemlani d
The $100 billion dollar opportunity in obesity drugs, Goldman Sachs analyst explains
08:00am, Saturday, 21'st Oct 2023
A Goldman Sachs report predicts that the total addressable market for weight loss drugs could reach $100 billion dollars by 2030. Popular weight loss drugs like Novo Nordisk's Ozempic (NVO) have pique
Pharma firms testing weight loss drugs for kids amid Ozempic craze
05:12pm, Friday, 20'th Oct 2023
Get ready for Ozem-kids! The pharmaceutical companies behind Ozempic, Mounjaro and Wegovy — which have exploded in popularity with adults looking to lose weight — are testing whether the drugs are
Drugmakers test weigh-loss shots for kids as young as 6
03:30pm, Friday, 20'th Oct 2023
Former FDA commissioner Dr. Scott Gottlieb joins 'Power Lunch' to discuss the latest weight loss headlines.
Options Traders Oh-Oh-Overjoyed With This Ozempic Trade
11:27am, Friday, 20'th Oct 2023
Subscribers to Chart of the Week received this commentary on Sunday, October 15.
1 Market-Beating Stock to Buy Near Its 52-Week High
09:30am, Thursday, 19'th Oct 2023
Eli Lilly's obesity diabetes medicine Mounjaro continues to show excellent prospects. It should be the biggest growth driver behind the company's sales in the coming years.
4 Ways to Grow $100,000 Into $1 Million for Retirement
09:13am, Thursday, 19'th Oct 2023
Realty Income's total returns deliver. Alphabet is still turning investors into millionaires.
GE HealthCare teams up with Novo Nordisk to treat diabetes without drugs
08:36am, Thursday, 19'th Oct 2023
GE HealthCare Technologies Inc. GEHC, -2.35% on Thursday said it is teaming up with Novo Nordisk NVO, -0.58% to develop an ultrasound treatment for type 2 diabetes and obesity.
Global market for anti-obesity drugs could reach $100B by 2030: Goldman Sachs
05:35pm, Tuesday, 17'th Oct 2023
A report from Goldman Sachs predicts that the total addressable market globally for weight loss drugs could reach $100 billion dollars in sales by 2030. The current market is estimated to be at $6 bil
